Formation of meprobamate from carisoprodol is catalysed by CYP2C19

Pharmacogenetics

Volumn 6, Issue 5, 1996, Pages 387-394

  Dalen P ^a   Alvan, G ^a   Wakelkamp, M ^a   Olsen, H ^b,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c Vinderen Hospital   (Norway)

Author keywords

Carisoprodol; CYP2C19; Debrisoquine; Mephenytoin; Meprobamate; Polymorphism; Sweden

Indexed keywords

ANALGESIC AGENT; CARISOPRODOL; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; MEPHENYTOIN; MEPROBAMATE; MUSCLE RELAXANT AGENT;

ADULT; ARTICLE; CATALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEALKYLATION; DROWSINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; HYDROXYLATION; HYPOTENSION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; SWEDEN; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; ANALGESICS; ARYL HYDROCARBON HYDROXYLASES; CARISOPRODOL; CYTOCHROME P-450 ENZYME SYSTEM; DEBRISOQUIN; FEMALE; HUMANS; MALE; MEPHENYTOIN; MEPROBAMATE; METABOLIC CLEARANCE RATE; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MUSCLE RELAXANTS, CENTRAL;

EID: 0029819847     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199610000-00002     Document Type: Article

References (35)

1. Adams H, Kerzee T, Morehead C. Carisoprodol-related death in a child. J Forensic Sci 1975: 20, 200-202.
2. Adedoyin A, Prakash C, O'Shea D, Blair I, Wilkinson G. Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. Pharmacogenetics 1994: 4, 27-38.
3. Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990: 39, 533-537.
4. Andersson T, Regårdh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992: 2, 25-31.
5. Bertilsson L, Dahl M-L, Ingelman-Sundberg M, Johansson I, Sjöqvist F. Interindividual and interethnic differences in polymorphic drug oxidation. Implications for drug therapy with focus on psychoactive drugs. In: Pacifici GM, Fracchia GN, eds: Advances in drug metabolism in man. European Commission, Luxembourg 1995: 85-136.
6. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J. Villén T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 1989: 45, 348-355.
7. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, Sjöqvist F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin: published erratum appears in Clin Pharmacol Ther 1994 Jun: 55(6): 648, Clin Pharmacol Ther 1992: 51, 388-397.
8. Brandslund I, A case of acute carisoprodol poisoning. Symptoms and metabolism: Ugeskr Laeger 1976: 138, 281-283.
9. Dahl M, Bertilsson L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 1993: 3, 61-70.
10. Eichelbaum M, Gross S. The genetic polymorphism of debrisoquine/ sparteine metabolism - Clinical aspects. In: Kalow W, ed. Pharmacogenetics of drug metabolism. New York: Pergamon Press, Inc, 1992: 625-648.
11. Elder N. Abuse of skeletal muscle relaxants. Am Fam Physician 1991: 44, 1223-1226.
12. Evans DA, Harmer D, Downham DY, Whibley EJ, Idle JR, Ritche J, Smith RL. The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions. J Med Genet 1983: 20, 321-329.
13. Giannini A, Price W, Giannini M. Contemporary drugs of abuse: published erratum appears in Am Fam Physician 1986 May: 33(51): 43. Am Fam Physician 1986: 33, 207-216.
14. Hollister L. The pre-benzodiazepine era. J Psychoactive Drugs 1983: 15, 9-13.
15. Lennard M, Silas J, Smith A, Tucker G, Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr 1977: 133, 161-166.
16. Littrell R, Hayes L, Stillner V, Carisoprodol (Soma): a new and cautious perspective on an old agent. South Med J 1993a: 86, 753-756.
17. Littrell R, Sage T, Miller W. Meprobamate dependence secondary to carisoprodol (Soma) use. Am J Drug Alcohol Abuse 1993b: 19, 133-134.
18. Luehr J, Meyerle K, Larson E, Eng L-m. Mail-order (veterinary) drug dependence: letter. JAMA 1990: 2, 657.
19. Manning J, Scandale L, Manning E, Gengo F. Central nervous system effects of meclizine and dimenhydrinate: evidence of acute tolerance to antihistamines. J Clin Pharmacol 1992: 32, 996-1002.
20. Morse R, Chua L. Carisoprodol dependence: a case report. Am J Drug Alcohol Abuse 1978: 5, 527-530.
21. Olsen H, Koppang E, Alván G, Mørland J. Carisoprodol elimination in humans. Ther Drug Monit 1994: 16, 337-340.
22. Roache J, Griffiths R. Lorazepam and meprobamate dose effects in humans: behavioral effects and abuse liability. J Pharmacol Exp Ther 1987: 243, 978-988.
23. Robin D, Hasan S, Lichtenstein M, Shiavi R, Wood A. Dose-related effect of triazolam on postural sway. Clin Pharmacol Ther 1991: 49, 581-588.
24. Rowland R, Tozer TN. Clinical pharmacokinetics, concepts and applications, 2nd edition. Philadelphia: Lea & Fabiger. 1989: 133, 459-461.
25. Rust G, Hatch R, Gums J. Carisoprodol as a drug of abuse: see comments. Arch Fam Med 1993: 2, 4, 429-932.
26. Sanz E, Villén T, Alm C, Bertilsson L. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 1989: 45, 495-499.
27. Sikdar S, Basu D, Malhotra A, Varma V, Mattoo S. Carisoprodol abuse: a report from India. Acta Psychiatr Scand 1993: 88, 302-303.
28. Sindrup SH, Brösen K, Hansen MG, Aaes JT, Overø KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993: 15, 11-17.
29. Skjelbo E, Brösen K, Hallas J, Gram LF, The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 1991: 49, 18-23.
30. Steiner E, Iselius L, Alván G, Lindsten J, Sjöqvist F. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther 1985: 38, 394-401.
31. Steiner E, Bertilsson L, Säwe J, Bertling I, Sjöqvist F. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 1988: 44, 431-435.
32. Tybring G, Bertilsson L. A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio. Pharmacogenetics 1992: 2, 241-243.
33. Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 1989: 45, 72-79.
34. Ward SA, Helsby NA, Skjelbo E, Brösen K, Gram LF, Breckenridge AM. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism - a panel study. Br J Clin Pharmacol 1991: 31, 689.
35. Wilkinson G, Guengerich P, Branch R. Genetic polymorphism of S-mephenytoin hydroxylation. In: Kalow W, ed. Pharmacogenetics of drug metabolism, New York: Pergamon Press, Inc. 1992: 657-685.